Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ATN-224 Clear all
Terminated Phase 3 Interventional Results available

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

NCT03403205
View directory record Official record
Conditions
Wilson Disease
Interventions
ALXN1840, SoC Therapy
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

NCT04560816
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840, Placebo, Moxifloxacin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 8, 2026, 10:08 AM EDT
Withdrawn Phase 1 Interventional

Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00560495
View directory record Official record
Conditions
Lung Cancer
Interventions
ammonium tetrathiomolybdate, immunoenzyme technique, laboratory biomarker analysis, Tc 99m sestamibi, radiation therapy
Drug · Other · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2022 · Synced Sep 8, 2026, 10:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

NCT06134375
View directory record Official record
Conditions
Triple Negative Breast Cancer, Residual Disease
Interventions
Tetrathiomolybdate, Capecitabine, Pembrolizumab
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
3
States / cities
Indianapolis, Indiana • Lebanon, New Hampshire • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 2 Interventional

Tetrathiomolybdate in Hormone Refractory Prostate Cancer

NCT00150995
View directory record Official record
Conditions
Prostate Cancer
Interventions
Tetrathiomolybdate
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 20, 2015 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840

NCT04422431
View directory record Official record
Conditions
Wilson Disease
Interventions
Bis-Choline Tetrathiomolybdate
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Sacramento, California • Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 3 Interventional

Study of Tetrathiomolybdate in Patients With Wilson Disease

NCT00004339
View directory record Official record
Conditions
Wilson Disease
Interventions
tetrathiomolybdate, trientine
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 8, 2006 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 2 Interventional

A Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris

NCT00113542
View directory record Official record
Conditions
Psoriasis
Interventions
Tetrathiomolybdate (TM)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 8, 2026, 10:08 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma

NCT00352742
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ATN-224 + bortezomib
Drug
Lead sponsor
Attenuon
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Fresno, California • West Hollywood, California • Fort Myers, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2008 · Synced Sep 8, 2026, 10:08 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma

NCT00383851
View directory record Official record
Conditions
Melanoma
Interventions
ATN-224, Temozolomide
Drug
Lead sponsor
Attenuon
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
17
States / cities
Tucson, Arizona • Encinitas, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Sep 8, 2026, 10:08 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

NCT00195091
View directory record Official record
Conditions
Breast Cancer
Interventions
Tetrathiomolybdate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

NCT04526210
View directory record Official record
Conditions
Wilson Disease
Interventions
ALXN1840, Bupropion Hydrochloride
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 2 Interventional

Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate

NCT00006332
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Tetrathiomolybdate
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 3 Interventional

Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

NCT00805805
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Tetrathiomolybdate, Placebo
Drug · Other
Lead sponsor
George Brewer
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.

NCT04526197
View directory record Official record
Conditions
Wilson Disease
Interventions
ALXN1840, Celecoxib
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 8, 2026, 10:08 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Study of ATN-224 in Patients With Prostate Cancer

NCT00405574
View directory record Official record
Conditions
Prostate Cancer
Interventions
ATN-224
Drug
Lead sponsor
Attenuon
Industry
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults

NCT05319899
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840, Omeprazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults

NCT05319912
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840 Enteric-coated Tablet, ALXN1840 Non-coated Capsule, Omeprazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma

NCT00176800
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
Tetrathiomolybdate (TM), Radiation, Surgery
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2016 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis

NCT00189176
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Tetrathiomolybdate
Drug
Lead sponsor
University of Michigan
Other
Eligibility
35 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 2 Interventional

Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma

NCT00176774
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Irinotecan, 5-Fluorouracil, Leucovorin, Tetrathiomolybdate
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Sep 8, 2026, 10:08 AM EDT
Completed Phase 1 Interventional

Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer

NCT01837329
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Tetrathiomolybdate
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Sep 8, 2026, 10:08 AM EDT